Drilldown: Medicines
More actions
Use the filters below to narrow your results.
generic:
None (7) ·
Apixaban (1) ·
Ascorbic acid (vitamin C) (1) ·
Azelastine (1) ·
Bisacodyl (1) ·
Dextromethorphan / Quinidine (1) ·
Docusate (sodium or calcium) (1) ·
Doxycycline (1) ·
Flecainide (1) ·
Icosapent ethyl (eicosapentaenoic acid ethyl ester, EPA-EE) (1) ·
Lactulose (1) ·
Ofloxacin (1) ·
Omega-3-acid ethyl esters (1) ·
Oseltamivir (1) ·
Polyethylene glycol 3350 (PEG 3350) (1) ·
Ticagrelor (1)
brand:
Astelin, Astepro (intranasal); Optivar (ophthalmic); with fluticasone as Dymista (1) ·
Brilinta (1) ·
Caplyta (1) ·
Colace (sodium), Surfak (calcium); many generics OTC (1) ·
Dulcolax, Correctol, Bisac-Evac (1) ·
Eliquis (1) ·
Floxin (oral, US brand discontinued); Ocuflox (ophthalmic); Floxin Otic (otic) (1) ·
Generic; huge OTC presence (1) ·
Kristalose, Constulose, Generlac, Enulose (1) ·
Lovaza, Omtryg (1) ·
MiraLAX (OTC), GlycoLax, GoLYTELY (with electrolytes for bowel prep), CoLyte, MoviPrep, NuLYTELY (1) ·
Nuedexta (1) ·
Nuplazid (1) ·
Qelbree (1) ·
REL-1017 / esmethadone (investigational; not yet FDA-approved as of mid-2024) (1) ·
Rexulti (1) ·
Tambocor (US brand discontinued) (1) ·
Tamiflu (1) ·
Trintellix (US), Brintellix (formerly) (1) ·
Vascepa (1) ·
Vibramycin, Doryx, Oracea, Adoxa, Monodox, Acticlate (1) ·
Viibryd (1)
classes:
mechanism:
None (11) ·
Partial agonist at D2 and 5HT1A. Antagonist at 5HT2A, α1A, α1B, α2C. More potent 5HT2A antagonism, 5HT1A partial agonism, and α1 antagonism (relative to D2 partial agonism) than aripiprazole, proposed to reduce akathisia and enhance affective/cognitive effects. (1) ·
Selective inverse agonist at 5HT2A receptors with weaker activity at 5HT2C. Has no significant dopamine D2 affinity, unique among approved antipsychotics. Inverse agonism (rather than antagonism) reduces constitutive 5HT2A receptor activity below baseline. (1) ·
Selective NET inhibitor (no significant DAT activity, distinguishes from amphetamine/methylphenidate). Also: 5HT1A receptor partial agonism, 5HT2B and 5HT7 receptor antagonism. The serotonergic actions may underlie better tolerability and possibly different efficacy spectrum than atomoxetine. (1) ·
'"`UNIQ--vote-0000004E-QINU`"' The EPA+DHA mix is biochemically and clinically distinct from icosapent ethyl'"`UNIQ--ref-0000004F-QINU`"'. (1) ·
'"`UNIQ--vote-000001F6-QINU`"' CYP3A4 (primary) and P-glycoprotein substrate; strong dual inhibitors or inducers materially shift exposure. Reversal: andexanet alfa for life-threatening bleeding; 4F-PCC commonly used off-label when andexanet unavailable'"`UNIQ--ref-000001F7-QINU`"'. (1) ·
'"`UNIQ--vote-00001067-QINU`"' Chronic use is associated with cathartic colon (colonic dilation, loss of haustration), hypokalemia, and laxative dependence; reserved for short-term use or bowel prep with breaks between courses'"`UNIQ--ref-00001068-QINU`"'. (1) ·
'"`UNIQ--vote-0000113A-QINU`"' Concomitant β-blocker or CCB is required when used for AF to prevent 1:1 atrial flutter conduction (flecainide can slow atrial rate to a level where AV conduction allows dangerous ventricular rates). CYP2D6 substrate'"`UNIQ--ref-0000113B-QINU`"'. (1) ·
'"`UNIQ--vote-0000132D-QINU`"' Electrolyte-balanced bowel-prep formulations are designed to be iso-osmotic with plasma so the volume passes through without net fluid or electrolyte shifts, the basis of their safety for whole-bowel evacuation. (1) ·
'"`UNIQ--vote-000013B1-QINU`"' Topical application minimizes systemic antihistaminic burden; the characteristic bitter taste with nasal use (drainage to oropharynx) is the main tolerability issue'"`UNIQ--ref-000013B2-QINU`"'. (1) ·
'"`UNIQ--vote-000014BC-QINU`"' Topical ophthalmic and otic formulations remain widely used in ENT and ophthalmology. Subject to all fluoroquinolone-class restrictions (tendinitis/rupture, peripheral neuropathy, QT prolongation)'"`UNIQ--ref-000014BD-QINU`"'. (1) ·
'"`UNIQ--vote-00001580-QINU`"' First FDA-approved treatment for PBA. The 10 mg quinidine daily dose is far below antiarrhythmic levels but sufficient to nearly fully inhibit CYP2D6, the basis of the combination's pharmacokinetic rationale'"`UNIQ--ref-00001581-QINU`"'. (1)
uses:
ADHD in children (6+), adolescents, and adults (FDA-approved 2021 for pediatric, 2022 for adult) (1) ·
Hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Investigational for psychosis in other dementias and as augmentation for depression. (1) ·
Investigational for major depressive disorder; trials underway (phase 3 mixed results) (1) ·
Major depressive disorder in adults (FDA-approved 2011) (1) ·
Major depressive disorder in adults (FDA-approved 2013). Notable for evidence of cognitive benefit (processing speed) that distinguishes it from other antidepressants. (1) ·
Schizophrenia (FDA-approved 2015). Adjunctive treatment of major depressive disorder (2015). '''Agitation associated with dementia due to Alzheimer disease''' (FDA-approved May 2023, first agent specifically approved for this problem). Investigational for PTSD (combined with sertraline). (1) ·
Schizophrenia (FDA-approved Dec 2019). Bipolar depression as monotherapy or adjunct to lithium/valproate (FDA-approved Dec 2021). (1) ·
'"`UNIQ--vote-00000050-QINU`"' (1) ·
'"`UNIQ--vote-000001F8-QINU`"', '"`UNIQ--vote-000001F9-QINU`"', '"`UNIQ--vote-000001FA-QINU`"' (1) ·
'"`UNIQ--vote-00000475-QINU`"', '"`UNIQ--vote-00000476-QINU`"', '"`UNIQ--vote-00000477-QINU`"', '"`UNIQ--vote-00000478-QINU`"', '"`UNIQ--vote-00000479-QINU`"', '"`UNIQ--vote-0000047A-QINU`"', '"`UNIQ--vote-0000047B-QINU`"', '"`UNIQ--vote-0000047C-QINU`"' (1) ·
'"`UNIQ--vote-00000C8F-QINU`"', '"`UNIQ--vote-00000C90-QINU`"', '"`UNIQ--vote-00000C91-QINU`"' (1) ·
'"`UNIQ--vote-00000E91-QINU`"', '"`UNIQ--vote-00000E92-QINU`"', '"`UNIQ--vote-00000E93-QINU`"' (1) ·
'"`UNIQ--vote-00000F5C-QINU`"', '"`UNIQ--vote-00000F5D-QINU`"' (1) ·
'"`UNIQ--vote-00001069-QINU`"', '"`UNIQ--vote-0000106A-QINU`"' (1) ·
'"`UNIQ--vote-0000113C-QINU`"', '"`UNIQ--vote-0000113D-QINU`"', '"`UNIQ--vote-0000113E-QINU`"' (1) ·
'"`UNIQ--vote-000012E5-QINU`"', '"`UNIQ--vote-000012E6-QINU`"', '"`UNIQ--vote-000012E7-QINU`"', '"`UNIQ--vote-000012E8-QINU`"' (1) ·
'"`UNIQ--vote-0000132E-QINU`"', '"`UNIQ--vote-0000132F-QINU`"', '"`UNIQ--vote-00001330-QINU`"' (1) ·
'"`UNIQ--vote-00001341-QINU`"', '"`UNIQ--vote-00001342-QINU`"' (1) ·
'"`UNIQ--vote-000013B3-QINU`"', '"`UNIQ--vote-000013B4-QINU`"', '"`UNIQ--vote-000013B5-QINU`"' (1) ·
'"`UNIQ--vote-000013CF-QINU`"', '"`UNIQ--vote-000013D0-QINU`"' (1) ·
'"`UNIQ--vote-000014BE-QINU`"', '"`UNIQ--vote-000014BF-QINU`"', '"`UNIQ--vote-000014C0-QINU`"', '"`UNIQ--vote-000014C1-QINU`"', '"`UNIQ--vote-000014C2-QINU`"' (1) ·
'"`UNIQ--vote-00001582-QINU`"' (1)
starting dose:
1 capsule (20/10 mg dextromethorphan/quinidine) PO once daily × 7 days, then 1 capsule BID (1) ·
10 mg PO once daily × 7 days, then 20 mg × 7 days, then 40 mg as target dose (take with food) (1) ·
10 mg PO once daily; may increase to 20 mg as tolerated, or decrease to 5 mg if needed (1) ·
100 mg PO BID; rickettsial 200 mg/d; doxy-PEP 200 mg within 72 hours after condomless sex (1) ·
100-200 mg PO once or twice daily; pediatric weight-based (1) ·
2 g PO BID with meals (4 g/d total) (1) ·
34 mg PO once daily (1) ·
4 g PO daily (as 4 x 1 g capsules once daily, or 2 capsules BID) (1) ·
42 mg PO once daily with food (no titration) (1) ·
5-15 mg PO once at bedtime; 10 mg PR for faster effect; bowel prep regimens use higher single doses (1) ·
50 mg PO BID; titrate to 100-200 mg BID; pill-in-pocket 200-300 mg PO single dose for AF conversion (1) ·
ACS/PCI: 180 mg PO loading dose, then 90 mg PO BID for 12 months; long-term post-MI: 60 mg BID (1) ·
Constipation: 15-30 mL PO daily (titrate to 1-2 soft stools/day); hepatic encephalopathy: 20-30 g (30-45 mL) PO/PR every 1-2 hours acutely until soft stools, then BID-QID to target 2-3 soft stools/day (1) ·
Constipation: 17 g (one capful) PO daily dissolved in 4-8 oz fluid; bowel prep: 4 L of PEG-electrolyte solution split-dose evening before and morning of procedure (1) ·
General supplementation 75-90 mg/d (RDA); scurvy treatment 100-1000 mg/d for several weeks; megadose claims unsupported (1) ·
Intranasal 0.1% or 0.15%: 1-2 sprays/nostril BID; ophthalmic 0.05%: 1 drop in each eye BID (1) ·
NVAF: 5 mg PO BID (2.5 mg BID if 2 of 3: age ≥80, weight ≤60 kg, serum creatinine ≥1.5 mg/dL); acute VTE: 10 mg BID for 7 days, then 5 mg BID (1) ·
Oral 200-400 mg BID; ophthalmic 1-2 drops in affected eye(s) q2-4h initially, then taper; otic 5-10 drops in affected ear BID (1) ·
Pediatric 6-11: 100 mg PO daily, titrate weekly to max 400 mg. Adolescent 12-17: 200 mg, max 400 mg. Adult: 200 mg, max 600 mg. (1) ·
Schizophrenia: 1 mg PO daily × 4 days, then 2 mg daily × 3 days, then 4 mg daily. MDD adjunct: 0.5-1 mg daily, increase to 2 mg max. AD agitation: 0.5 mg daily, titrate to 2-3 mg daily. (1) ·
Treatment: 75 mg PO BID × 5 days (adult); pediatric weight-based; prophylaxis: 75 mg PO once daily × 7-10 days (1) ·
Trials use 25 mg or 50 mg PO daily (1)
preparations:
0.1%, 0.15% intranasal spray; 0.05% ophthalmic solution; combination Dymista (azelastine 0.137 mg + fluticasone 50 mcg/spray) (1) ·
0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg tablets (1) ·
0.5 g, 1 g capsules (1) ·
1 g soft gelatin capsules containing ~465 mg EPA + ~375 mg DHA as ethyl esters (1) ·
10 g/15 mL solution (Constulose); 10 g, 20 g powder packets (Kristalose) (1) ·
10 mg, 20 mg, 40 mg tablets (1) ·
10 mg, 34 mg capsules/tablets (1) ·
100 mg, 150 mg, 200 mg extended-release capsules (can be sprinkled on food) (1) ·
100, 250, 500, 1000 mg tablets, chewables, gummies, effervescent; IV (specialty) (1) ·
17 g (OTC) and 14 g (Rx) powder packets; 238, 510, 527 g bottles; PEG-electrolyte preparations 4 L (GoLYTELY, NuLYTELY) (1) ·
2.5 mg, 5 mg tablets (1) ·
20 mg dextromethorphan HBr / 10 mg quinidine sulfate capsules (1) ·
200, 300, 400 mg tablets (mostly generic now); 0.3% ophthalmic solution; 0.3% otic solution (1) ·
30, 45, 75 mg capsules; 6 mg/mL oral suspension (1) ·
42 mg capsules (1) ·
5 mg enteric-coated tablets; 10 mg rectal suppositories; OTC and Rx (1) ·
5 mg, 10 mg, 20 mg tablets (1) ·
50 mg, 75 mg, 100 mg, 150 mg tablets and capsules; delayed-release; suspension; IV (1) ·
50, 100, 150 mg tablets (1) ·
50, 100, 250 mg capsules; 50 mg/5 mL syrup; OTC (1) ·
60, 90 mg tablets (1) ·
Investigational oral capsule (1)
fda max:
1 capsule BID (40 mg DXM / 20 mg quinidine per day) (1) ·
10 mg BID for the first 7 days of acute VTE; otherwise 5 mg BID (1) ·
150 mg/d (treatment) (1) ·
2 sprays/nostril BID (1) ·
20 mg/d (1) ·
30 mg/d for short-term use (1) ·
34 mg/d (1) ·
4 g/d (2) ·
4 mg/d (schizophrenia); 3 mg/d (AD agitation); 3 mg/d (MDD adjunct) (1) ·
40 mg/d (1) ·
400 mg/d (1) ·
400 mg/d (pediatric); 600 mg/d (adult) (1) ·
42 mg/d (1) ·
800 mg/d (1) ·
90 mg BID (acute year); 60 mg BID (chronic post-MI) (1) ·
Indication-specific; bowel prep regimens reach 4 L cumulative (1) ·
Indication-specific; HE may require high-volume dosing (1) ·
Not yet approved (1) ·
UL 2000 mg/d in adults (1) ·
~200 mg/d for most indications; higher doses for severe infections (1) ·
~500 mg/d typical (1)
routes:
onset:
1-3 days (1) ·
15 minutes (1) ·
4-6 weeks for full antidepressant effect (claimed earlier onset for some patients due to 5HT1A partial agonism) (1) ·
ADHD symptom improvement reported within 1-2 weeks (faster than atomoxetine which takes 4-6 weeks) (1) ·
AF conversion within hours of single PO dose (1) ·
Antiplatelet effect within 30 minutes of loading dose (faster than clopidogrel) (1) ·
Antipsychotic effect over weeks (1) ·
Benefit over weeks of dosing (1) ·
Constipation: 1-3 days; bowel prep: 1-3 hours after starting (1) ·
Constipation: 24-48 hours; HE: ammonia reduction within hours of stool production (1) ·
Days for symptom improvement in scurvy (1) ·
Hours (2) ·
PBA episode reduction within 1-2 weeks (1) ·
Peak anticoagulant effect 3-4 hours (1) ·
PO 6-12 hours; PR 15-60 minutes (1) ·
Rapid (within 1 week in trials) (1) ·
Symptom shortening detectable within 24-48 hours of starting (small absolute benefit; ~1 day reduction in symptom duration) (1) ·
Triglyceride lowering at 2-4 weeks; max at 8 weeks (1) ·
Triglyceride lowering at 4-8 weeks; CV benefit emerges over months (1) ·
Typical antidepressant 4-6 week onset (1) ·
Weeks for psychosis/depression; AD agitation benefit emerges over weeks (1)
duration: (Click arrow to add another value)
halflife:
16-22 hours'"`UNIQ--ref-0000047D-QINU`"' (1) ·
Dextromethorphan substantially prolonged by quinidine's CYP2D6 inhibition (typical extensive metabolizers see ~10× higher AUC); quinidine ~6-8 hours'"`UNIQ--ref-00001583-QINU`"' (1) ·
Not formally established (1) ·
Not meaningfully described (1) ·
Not meaningfully described (negligible systemic absorption) (1) ·
Not meaningfully described — lactulose is not significantly absorbed (1) ·
Not well characterized; tissue incorporation over weeks'"`UNIQ--ref-00000051-QINU`"' (1) ·
Variable; effect dependent on local intestinal action rather than systemic kinetics'"`UNIQ--ref-0000106B-QINU`"' (1) ·
~10-20 days (steady-state body pool); single dose plasma ~2 hours (1) ·
~12 hours'"`UNIQ--ref-000001FB-QINU`"' (1) ·
~14 hours (adults); longer in elderly and renal impairment'"`UNIQ--ref-0000113F-QINU`"' (1) ·
~18 hours (terminal) (1) ·
~22 hours; longer 54 hours (desmethylazelastine, active metabolite)'"`UNIQ--ref-000013B6-QINU`"' (1) ·
~25 hours (1) ·
~57 hours (parent), ~200 h (active metabolite) (1) ·
~6-10 hours (oseltamivir carboxylate, the active metabolite)'"`UNIQ--ref-00000E94-QINU`"' (1) ·
~66 hours (1) ·
~7 hours (1) ·
~7 hours (parent); ~9 hours (active AR-C124910XX metabolite, accounts for ~30-40% of activity)'"`UNIQ--ref-00000C92-QINU`"' (1) ·
~89 hours (EPA, the active metabolite)'"`UNIQ--ref-000013D1-QINU`"' (1) ·
~9 hours'"`UNIQ--ref-000014C3-QINU`"' (1) ·
~91 hours (1)
bioavailability:
<0.1% systemic absorption (PEG 3350 is too large to absorb intact) (1) ·
<3% systemic absorption (the basis of the safety and mechanism)'"`UNIQ--ref-00000F5E-QINU`"' (1) ·
Adequate oral bioavailability with extended-release formulation (1) ·
Improved with food'"`UNIQ--ref-00000052-QINU`"' (1) ·
Increased substantially via CYP2D6 inhibition'"`UNIQ--ref-00001584-QINU`"' (1) ·
Intranasal ~40% systemic; ophthalmic minimal'"`UNIQ--ref-000013B7-QINU`"' (1) ·
Limited but adequate; take with food (1) ·
Local action; minimal systemic effect (1) ·
Low systemic absorption (enteric coating delivers drug to colon)'"`UNIQ--ref-0000106C-QINU`"' (1) ·
Not characterized; oral dosing once daily (1) ·
Oral bioavailability suitable for daily dosing (1) ·
Substantially improved with high-fat meal; take with food'"`UNIQ--ref-000013D2-QINU`"' (1) ·
~36% (oral)'"`UNIQ--ref-00000C93-QINU`"' (1) ·
~50% (oral; not significantly affected by food)'"`UNIQ--ref-000001FC-QINU`"' (1) ·
~70-90% at typical doses; saturable at high doses (>500 mg) (1) ·
~72% (with food); much lower fasting (~36%) (1) ·
~75% (1) ·
~75% (oral, as the active carboxylate after hepatic esterase activation)'"`UNIQ--ref-00000E95-QINU`"' (1) ·
~90% (oral)'"`UNIQ--ref-00001140-QINU`"' (1) ·
~95% (1) ·
~95% (oral)'"`UNIQ--ref-000014C4-QINU`"' (1) ·
~95% (oral; reduced by dairy, antacids, iron via divalent-cation chelation, though less than for tetracycline itself)'"`UNIQ--ref-0000047E-QINU`"' (1)
pregnancy:
None (2) ·
'''Avoid in pregnancy where alternatives exist''' (animal cartilage toxicity; class-wide concern).<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Generally considered acceptable for short-term use.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Generally considered safe (minimal systemic absorption).<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Generally considered safe due to minimal systemic absorption.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Generally considered safe.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Generally used when influenza treatment is indicated; pregnancy is a recognized risk factor for severe influenza.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Investigational (1) ·
Limited data (1) ·
Limited data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited data; avoid (1) ·
Limited data; National Pregnancy Registry available (1) ·
Limited data; National Pregnancy Registry for Atypical Antipsychotics (1) ·
Limited data; quinidine has been used in pregnancy as antiarrhythmic.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited data; second-line to intranasal corticosteroids or PO loratadine/cetirizine.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited data; weigh against alternatives.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited data; weigh benefits/risks (2) ·
Limited human data<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Safe at routine doses; routinely supplemented in pregnancy.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Use in fetal SVT (transplacental antiarrhythmic therapy) is established; otherwise weigh against alternatives.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
legal:
Investigational (1) ·
OTC (Astepro 0.15%) and [[USLegal:Prescription only|Rx-only]] (other intranasal, ophthalmic, Dymista) in US (1) ·
OTC (MiraLAX) and [[USLegal:Prescription only|Rx-only]] (electrolyte solutions for bowel prep) in US (1) ·
OTC in US (3) ·
Rx (4) ·
Rx, '''not a controlled substance''' (no DEA scheduling) (1) ·
Rx. FDA black-box warning for increased mortality in elderly patients with dementia-related psychosis (class warning shared with all antipsychotics) (1) ·
[[USLegal:Prescription only|Rx-only]] in US (6) ·
[[USLegal:Prescription only|Rx-only]] in US. '''Contraindicated in structural heart disease''' — CAST trial (1989) showed increased mortality from class IC agents in patients with prior MI; modern use is limited to structurally normal hearts'"`UNIQ--ref-00001141-QINU`"' (1) ·
[[USLegal:Prescription only|Rx-only]] in US. Carries a '''Boxed Warning''' for bleeding risk and against aspirin maintenance doses above 100 mg/d (reduces ticagrelor efficacy, per PLATO subgroup analysis)'"`UNIQ--ref-00000C94-QINU`"' (1) ·
[[USLegal:Prescription only|Rx-only]] in US. Carries the same fluoroquinolone-class '''Boxed Warnings''' as ciprofloxacin/levofloxacin'"`UNIQ--ref-000014C5-QINU`"' (1) ·
[[USLegal:Prescription only|Rx-only]] in US. Caution with QT-prolonging medicines (quinidine itself is class IA antiarrhythmic, and the dose here, though sub-antiarrhythmic, still contributes to QT)'"`UNIQ--ref-00001585-QINU`"' (1)
Showing below up to 22 results in range #1 to #22.